Diligence memo · auto-generated · as of July 2, 2026
Gaingels Glyphic Bio 2025 LLC
Gaingels Glyphic Bio 2025 LLC looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Gaingels Glyphic Bio 2025 LLC operates in Biotech / Pharma, based in BURLINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gaingels Glyphic Bio 2025 LLC has raised $176K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $176K on 2025-09-30.
Most recent recorded round closed around 2025-09-30.
Valuation (modeled)modeled
Provath models Gaingels Glyphic Bio 2025 LLC at approximately $379K (range $96K–$874K). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.45× the median modeled value of Pre-Seed Biotech / Pharma companies in 2025–2027 (6 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 9 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 13% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Cosmos Pharmaceuticals, LLC, Stratum Biosciences Inc., Amptiv Biosciences, Inc., Fairfield Bio, Inc., Gaingels Aether Bio 2025 LLC.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.